COMMUNIQUÉS West-GlobeNewswire

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program
15/09/2026
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimester Dr. Gordon Sanghera CBE [...]
Transactions in connection with share buy-back program
15/09/2026
Company announcement no. 35 - 26 15 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections
15/09/2026
MELBOURNE, Australia, Sept. 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral [...]
C4X Discovery establishes in vivo proof of concept for its PAD4 inhibitor programme
15/09/2026
A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis 15 September 2026 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company [...]
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
15/09/2026
CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathy Detailed interim Phase 1 data to be released in a virtual event after [...]
Eleva separates Bryotechnology platform and clinical-stage Factor H biotherapeutic into independent companies
15/09/2026
Eleva Biologics will seek strategic partnerships for development and manufacturing of first-in-class and previously inaccessible biologics discovered with the Bryotechnology platform One04 Therapeutics will focus on [...]
Children’s National ranked among top children’s hospitals nationwide and highest in the DMV by U.S. News & World Report
15/09/2026
Ranked in all 11 specialties, with top 10 honors in neurology and neurosurgery, cancer, orthopedics, gastroenterology and GI surgery, neonatology, and diabetes and endocrinology Washington, DC, Sept. 15, 2026 (GLOBE [...]
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
15/09/2026
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “ Company ” [...]
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
15/09/2026
SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health [...]
From Former Patient to Clinical Leader: Oxford Treatment Center Promotes Kate Bell to Outpatient Clinical Manager
15/09/2026
OXFORD, Miss., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Oxford Treatment Center is pleased to announce the promotion of Kate Bell, NCC, LPC , to Outpatient Clinical Manager. Bell first came to Oxford Treatment Center as a [...]
Ascendis Announces Planned $400 Million Share Repurchase Program
15/09/2026
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s [...]
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
15/09/2026
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and [...]
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
14/09/2026
BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today [...]
DLH Appoints Brooke Pierce President of Health Business Group
14/09/2026
ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
PetMeds Appoints Andrew Parry as Chief Technology Officer
14/09/2026
DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, [...]
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
14/09/2026
Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for [...]
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
14/09/2026
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in [...]
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
14/09/2026
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic [...]
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
14/09/2026
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to [...]

Pages